To the best of our knowledge, this is the first study to evaluate the cost-effectiveness of atezolizumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer with different PD-L1 expression status from the Chinese health sector perspective. This evidence concerns the gene CD274 and non-small cell lung carcinoma.